What does the CRO of the future look like? In diagnostics we seem to be inundated with more platforms, more analytes more “-omics” and more pathways. How do we make sense of it all? What is the future of multi-omic analysis and what role will digital pathology play in understanding biological pathways, clinical trials, multi-omics and the development of companion diagnostics?
Christopher Ung, Chief Scientific Business Officer at CellCarta, has 22 years of experience in the field of digital pathology. He has made a significant impact by leading innovative solutions in the realm of companion diagnostics. He led the development of HerceptTest, and in 2009 built and connected pathology labs in four different countries with a digital pathology system. Christopher 's passion for digital pathology stems from a belief in the potential for technology to revolutionize the way pathology is practiced. He is particularly interested in the application of machine learning and artificial intelligence in digital pathology to improve the accuracy of developing and interpreting high complexity and high-density biomarkers for clinical trials and companion diagnostics.
In addition to what the CRO of the future will look like, we discuss the role of digital pathology in clinical trials, multi-omics and the development of companion diagnostics. Will digital pathology play a supportive role, or will it be the centerpiece?
